E. Bucci

发表

Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapy

E. Clementi, C. Fortis, G. Citterio, 1994, Cancer Immunology, Immunotherapy.

Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes

D. Noonan, A. Albini, A. Bruno, 2015, PloS one.

In vivo administration of GM‐CSF promotes the clearance of apoptotic cells: effects on monocytes and polymorphonuclear leukocytes

C. Rugarli, A. Manfredi, S. Heltai, 2000, Journal of leukocyte biology.

Capecitabine in Breast Cancer: The Issue of Cardiotoxicity During Fluoropyrimidine Treatment

D. Noonan, A. Albini, O. Gottardi, 2010, The breast journal.

Sequential therapy with recombinant Interleukin-2 (rIL-2) and α-interferon (IFN) for advanced renal cell cancer (rcc) : a preliminary report

A. Borri, C. Besana, C. Rugarli, 1994 .

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation

M. Biffi, M. Tresoldi, C. Besana, 2005, Cancer Immunology, Immunotherapy.

The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker

C. Garlanda, D. Noonan, A. Albini, 2010, Journal of Translational Medicine.

Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.

D. Noonan, A. Albini, F. Donatelli, 2011, Future cardiology.

Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-alpha increase during interleukin-2 therapy.

C. Fortis, G. Citterio, L. Galli, 1995, Clinical immunology and immunopathology.

ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy

Renzo Boldorini, Ottavio Beretta, O. Beretta, 2013, Cancer Chemotherapy and Pharmacology.

Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.

M. Tresoldi, A. Borri, C. Besana, 1994, European journal of cancer.

Intensive chemotherapy with recombinant-human granulocyte-macrophage colony stimulating factor (r-hu-gm-csf) for small cell lung cancer (sclc): a pilot study

M. Tresoldi, M. Marcatti, A. Borri, 1994 .

Isolated left ventricular filling abnormalities may predict interleukin-2-induced cardiovascular toxicity.

S. Chierchia, G. Fragasso, M. Tresoldi, 1996, Journal of Immunotherapy with Emphasis on Tumor Immunology.

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.

S. Barni, R. Labianca, D. Amadori, 2021, European journal of cancer.

Response to the Letter to the Editor

D. Noonan, A. Albini, O. Gottardi, 2011 .

An apparent primitive mass of the mesentery

Andrea Ferretti, M. De Luca, E. Bucci, 2022, Medicine.